UB Paderborn / Katalog / Suche / in CDI

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference

Journal of viral hepatitis, 2016-02, Vol.23 (S1), p.1-12

2016

Volltextzugriff (PDF)

Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

Journal of viral hepatitis, 2015-02, Vol.22 (2), p.120-127

2015

Volltextzugriff (PDF)

Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease

Journal of viral hepatitis, 2008-02, Vol.15 (2), p.145-154

2008

Volltextzugriff (PDF)

CD80/CD28 co‐stimulation in human brucellosis

Clinical and experimental immunology, 2006-12, Vol.146 (3), p.400-408

2006

Volltextzugriff (PDF)

Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B

Journal of hepatology, 2017, Vol.66 (1), p.S480-S480

2017

Volltextzugriff (PDF)

Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab

Hippokratia, 2013-01, Vol.17 (1), p.91-93

2013

Volltextzugriff (PDF)

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study

Gut, 2011-08, Vol.60 (8), p.1109-1116

2011

Volltextzugriff (PDF)

766 HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe−) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY

Journal of hepatology, 2013-04, Vol.58, p.S312-S312

2013

Volltextzugriff (PDF)

737 POLYMORPHISMS NEAR THE IL28B GENE ARE NOT ASSOCIATED WITH RESPONSE TO PEGINTERFERON IN HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS

Journal of hepatology, 2013-04, Vol.58, p.S299-S299

2013

Volltextzugriff (PDF)

511 HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS

Journal of hepatology, 2012-04, Vol.56, p.S201-S202

2012

Volltextzugriff (PDF)

714 HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT

Journal of hepatology, 2011-03, Vol.54, p.S286-S287

2011

Volltextzugriff (PDF)

270 CD4+CD25+FOXP3+ TREGS: DO THEY INHIBIT HCV CLEARANCE IN CHRONIC HCV GENOTYPE 1 INFECTION?

Journal of hepatology, 2011-03, Vol.54, p.S111-S111

2011

Volltextzugriff (PDF)

1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

Journal of hepatology, 2010, Vol.52, p.S390-S391

2010

Volltextzugriff (PDF)

Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study

Hippokratia, 2014-01, Vol.18 (1), p.57-64

2014

Volltextzugriff (PDF)

Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks

Hepatology (Baltimore, Md.), 2008-07, Vol.48 (1), p.99-108

2008

Volltextzugriff (PDF)

Virologic response and resistance to lamivudine in patients with chronic hepatitis B: a ten-year retrospective analysis

Hippokratia, 2012-01, Vol.16 (4), p.342-346

2012

Volltextzugriff (PDF)

Randomized trial of peginterferon alfa‐2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

Hepatology (Baltimore, Md.), 2010-10, Vol.52 (4), p.1201-1207

2010

Volltextzugriff (PDF)

Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center

Hippokratia, 2007-10, Vol.11 (4), p.210-215

2007

Volltextzugriff (PDF)

Prevalence of Hepatitis C Virus Infection in a Cohort of Pregnant Women in Northern Greece and Transmission of HCV from Mother to Child

European journal of epidemiology, 2001-01, Vol.17 (3), p.263-266

2001

Volltextzugriff (PDF)

FRI-157 - Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B

Journal of hepatology, 2017, Vol.66 (1), p.S480-S480

2017

Volltextzugriff (PDF)

Hepatocellular carcinoma risk in HB eAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

Journal of viral hepatitis, 2015-02, Vol.22 (2), p.120-127

2015

Volltextzugriff (PDF)

Reevaluation of the Effect of Levamisole in Chronic Brucellosis: In Vitro and in Vivo Effect on Monocyte Phagocytosis

Immunopharmacology and immunotoxicology, 1984, Vol.6 (3), p.135-146

1984

Volltextzugriff (PDF)

Interferon-α2b treatment of chronic hepatitis C in haemodialysis patients

Nephrology, dialysis, transplantation, 1995-10, Vol.10 (10), p.1834-1837

1995

Volltextzugriff (PDF)

Levamisole in the Treatment of Chronic Brucellosis

Immunopharmacology and immunotoxicology, 1980, Vol.2 (1), p.85-97

1980

Volltextzugriff (PDF)

The effect of loratadine on activated cells of the nasal mucosa in patients with allergic rhinitis

Journal of investigational allergology & clinical immunology, 1993-07, Vol.3 (4), p.192

1993

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference

Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

Cytokine mRNA expression in hepatitis C virus infection: TH1 predominance in patients with chronic hepatitis C and TH1-TH2 cytokine profile in subjects with self-limited disease

CD80/CD28 co‐stimulation in human brucellosis

Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B

Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study

766 HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe−) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY

737 POLYMORPHISMS NEAR THE IL28B GENE ARE NOT ASSOCIATED WITH RESPONSE TO PEGINTERFERON IN HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS

511 HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS

714 HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT

270 CD4+CD25+FOXP3+ TREGS: DO THEY INHIBIT HCV CLEARANCE IN CHRONIC HCV GENOTYPE 1 INFECTION?

1011 RISK AND PREDICTORS OF MORTALITY OR HEPATOCELLULAR CARCINOMA AMONG ENTECAVIR- OR ADEFOVIR-TREATED CHRONIC HEPATITIS B PATIENTS WITH EVIDENCE OF HEPATIC DECOMPENSATION

Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study

Entecavir therapy for lamivudine‐refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks

Virologic response and resistance to lamivudine in patients with chronic hepatitis B: a ten-year retrospective analysis

Randomized trial of peginterferon alfa‐2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center

Prevalence of Hepatitis C Virus Infection in a Cohort of Pregnant Women in Northern Greece and Transmission of HCV from Mother to Child

FRI-157 - Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B

Hepatocellular carcinoma risk in HB eAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

Reevaluation of the Effect of Levamisole in Chronic Brucellosis: In Vitro and in Vivo Effect on Monocyte Phagocytosis

Interferon-α2b treatment of chronic hepatitis C in haemodialysis patients

Levamisole in the Treatment of Chronic Brucellosis

The effect of loratadine on activated cells of the nasal mucosa in patients with allergic rhinitis

Suchergebnisse filtern